Articles From: Sprott Inc. Announces 2014 Third Quarter Results to Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial


Sprott Inc. Announces 2014 Third Quarter Results Canada NewsWire TORONTO , Nov.
Sign-up for Sprott Inc. Announces 2014 Third Quarter Results investment picks
Ne t Loss Reduced by 35% and Operating Cash Burn Cut by 48% From Third Quarter 2013 WALTHAM, Mass., Nov.
Sign-up for BG Medicine Reports Third Quarter 2014 Financial Results investment picks
http://media.marketwire.com/attachments/201308/178124_cti-1half.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158516&ProfileId=051205&sourceType=1 LAKE BARRINGTON, IL --
Sign-up for CTI Industries Corporation Reports Return to Profit in Third Quarter and for Nine Months investment picks
* Third quarter revenue decreased 10.2% year-over-year to $61.8 million * Third quarter operating income decreased 32.7% to $5.2 million, or 8.4% of sales * Third quarter net income decreased 38.8% year-over-year to $4.3 million, or $0.26 per share * Full Year 2014 net income expected to be in the range of $16.5 million to $17.0 million, or $0.99 to $1.02 per share CARLSTADT, N.J. , Nov.
Sign-up for Jinpan International Reports Third Quarter 2014 Financial Results investment picks
MAXIMUS (NYSE: MMS), a leading provider of government services worldwide, today reported financial results for its fourth quarter and fiscal year ended September 30, 2014.
Sign-up for MAXIMUS Reports Fourth Quarter and Full Year Financial Results for Fiscal 2014 investment picks
LEXINGTON, Mass., Nov.
Sign-up for T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0978686001&sourceType=1 http://www.ccnmatthews.com/logos/20111003-advlogful.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Alderon Appoints Two New Hebei Directors to the Board investment picks
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences: Live, listen-only webcasts of the presentations may be accessed by visiting the investors section of the company’s website at investors.foundationmedicine.com .
Sign-up for Foundation Medicine to Present at Upcoming Investor Conferences investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0978714001&sourceType=1 http://media3.marketwire.com/logos/20130113-cgi_logo_b.jpg MONTREAL, QUEBEC --
Sign-up for CGI posts strong Q4 and fiscal 2014 results investment picks
sPower and Camborne Capital Receive More Than 105,500 High Efficiency Honey M solar Modules from Trina Solar CHANGZHOU, China , Nov.
Sign-up for Trina Solar Supplies 28.5MW of Modules to Large-Scale Projects in UK investment picks
NETANYA, Israel , November 13, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel ltd. Announces Annual General Meeting of Shareholders investment picks
SANTA MONICA, Calif.
Sign-up for Macerich To Host Investor Day investment picks
Ascent Solar Technologies, Inc. (“Ascent”) (NASDAQ:ASTI), a manufacturer of state-of-the-art, flexible thin-film photovoltaic modules, integrated into off-grid applications and the company’s EnerPlex™ series of consumer products, announced today the Company’s third quarter results ended September 30, 2014.
Sign-up for Ascent Solar Announces Q3 Results and Reiterates Full Year Revenue Guidance of $5 - $6 Million Dollars investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0978760001&sourceType=1 http://media3.marketwire.com/logos/20130820-Zinc.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Canadian Zinc Reports Financial Results for Third Quarter 2014 investment picks
Mallinckrodt plc (NYSE: MNK) has been informed by the U.S. Food and Drug Administration (FDA) that the agency has reason to believe that the company’s methylphenidate hydrochloride extended-release (ER) tablets, USP (CII) may not be therapeutically equivalent to the category reference drug Concerta®. As a result, the agency indicated that it has reclassified Mallinckrodt’s ANDA 202608 for methylphenidate ER dosage strengths of 27mg, 36 mg and 54 mg from AB (freely substitutable at the pharmacy level) to BX (presumed to be therapeutically inequivalent). The agency said that this change was based on the application of its new Draft Guidance for determining bioequivalence of methylphenidate hydrochloride products just published on November 6, 2014.
Sign-up for Mallinckrodt plc Responds to FDA’s Expected Reclassification of Methylphenidate ER investment picks
Pro Forma Results: - Adjusted Net Income of $35.5 Million or $0.40 per Fully Diluted Share for the Third Quarter; $116.2 Million or $1.31 per Fully Diluted Share for the First Nine Months 2014 - Adjusted EBITDA of $57.8 Million for the Third Quarter; $193.7 Million for the First Nine Months 2014 Assets Under Administration of $212.8 Billion; up 11.3% From the Year Ago Period Following Review by Independent External Counsel and Forensic Accounting Firm, RCS Capital's Audit Committee and Management Team Remain Confident in The Company's Reported Historical Financials, Accounting, and Internal Controls $57 - $65 Million Revenue Synergies and Cost Savings Expected to be in Place for January 1, 2015; Additional Synergies Expected in 2015 9,139 Total Advisors on Platform; 97.8% Annualized Advisor Retention; Solid Retail Margin Expansion in Third Quarter; Robust Recruiting Pipeline Wholesale Distribution Equity Sales of $2.3 Billion for the Third Quarter; $8.2
Sign-up for RCS Capital Corporation Announces Third Quarter 2014 Operating Results investment picks
SHENZHEN, China , Nov.
Sign-up for CNIT Secures RMB 1 Billion Revolving Credit Line with China CITIC Bank investment picks
Evaluation based on ability to execute and completeness of vision ST.
Sign-up for Amdocs Positioned in Leader's Quadrant for Integrated Revenue and Customer Management (IRCM) for CSPs investment picks
ROSH HAAYIN, Israel , Nov.
Sign-up for Pointer Telocation Reports Q3 2014 Financial Results investment picks
Net Cash from operating activities of NIS 9.1 million (US$ 2.5 million) in Q3 2014 YAVNE, Israel , Nov.
Sign-up for G. Willi-Food Reports Q3 2014 Sales Up 0.1% From Q3 2013 Sales investment picks
New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination Canada NewsWire MONTREAL , Nov.
Sign-up for New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination investment picks
Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial Canada NewsWire MONTREAL , Nov.
Sign-up for Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Sprott Inc. Announces 2014 Third Quarter Results to Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent